Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Oct 2022
Historique:
received: 07 04 2022
revised: 23 06 2022
accepted: 24 06 2022
pubmed: 8 7 2022
medline: 17 8 2022
entrez: 7 7 2022
Statut: ppublish

Résumé

A series of quinoline and quinazoline analogs were designed and synthesized as new tubulin polymerization (TP) and histone deacetylases (HDAC) inhibitors. Compounds 12a and 12d showed the best cytotoxicity activities against a panel of human cancer cell lines with an averaged IC

Identifiants

pubmed: 35797900
pii: S0223-5234(22)00475-5
doi: 10.1016/j.ejmech.2022.114573
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Histone Deacetylase Inhibitors 0
Hydroxamic Acids 0
Quinolines 0
Repressor Proteins 0
Tubulin 0
HDAC8 protein, human EC 3.5.1.98
Histone Deacetylases EC 3.5.1.98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114573

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

Camille Hauguel (C)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Sarah Ducellier (S)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Immunologie anti-tumorale et immunothérapie des cancers, 94805, Villejuif, France.

Olivier Provot (O)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Nada Ibrahim (N)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Diana Lamaa (D)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Coline Balcerowiak (C)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Boris Letribot (B)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Megane Nascimento (M)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Immunologie anti-tumorale et immunothérapie des cancers, 94805, Villejuif, France.

Vincent Blanchard (V)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Laurie Askenatzis (L)

Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198, Gif-sur-Yvette, France.

Helene Levaique (H)

Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198, Gif-sur-Yvette, France.

Jérôme Bignon (J)

Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198, Gif-sur-Yvette, France.

Francesco Baschieri (F)

Université Paris-Saclay, Inserm, Institut Gustave Roussy, Dynamique des cellules tumorales, 94805, Villejuif, France.

Cyril Bauvais (C)

SYNSIGHT, 91400, Orsay, France.

Guillaume Bollot (G)

SYNSIGHT, 91400, Orsay, France.

Dolor Renko (D)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Alain Deroussent (A)

Université Paris-Saclay, CNRS, Institut Gustave Roussy, Aspects métoboliques et systémiques de l'oncogenèse pour de nouvelles approches thérapeutiques, 94805, Villejuif, France.

Bastien Prost (B)

Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au service de l'innovation thérapeutique, 92296, Châtenay-Malabry, France.

Marie-Catherine Laisne (MC)

Université Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences, 38000, Grenoble, France.

Sophie Michallet (S)

Université Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences, 38000, Grenoble, France.

Laurence Lafanechère (L)

Université Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences, 38000, Grenoble, France.

Sébastien Papot (S)

Université de Poitiers, CNRS, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), 86073, Poitiers, France.

Guillaume Montagnac (G)

Université Paris-Saclay, Inserm, Institut Gustave Roussy, Dynamique des cellules tumorales, 94805, Villejuif, France.

Christine Tran (C)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Mouad Alami (M)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Sebastien Apcher (S)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Immunologie anti-tumorale et immunothérapie des cancers, 94805, Villejuif, France.

Abdallah Hamze (A)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France. Electronic address: abdallah.hamze@universite-paris-saclay.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH